14/07/2026 Innovent Biologics and Spero Therapeutics announced an exclusive licensing agreement for IBI355 for the treatment of immune-mediated diseases Innovent Biologics and Spero Therapeutics announced an exclusive licensing agreement for IBI355 for the treatment of immune-mediated diseases (Ref) Innovent Biologics and Spero Therapeutics announced an exclusive license agreement for IBI355 (SP001; a third-generation Fc-silent anti-CD40L antibody) for immune-mediated disease

08/06/2026 Telitacicept received NMPA conditional approval for the treatment of IgA Nephropathy in China Telitacicept received NMPA approval for the treatment of Sjögren’s disease in China Alvotech announced FDA acceptance of a BLA for AVT16, a proposed interchangeable biosimilar to Entyvio® Telitacicept received NMPA conditional approval for the treatment of IgA Nephropathy in China (Ref) Vor Bio and RemeGen Co. announced that China’s National Medicinal Products Administrati

03/06/2026 Johnson & Johnson late-breaking results showed nipocalimab significantly reduced SLE disease activity in a Phase 2 study Johnson & Johnson announced biomarker exploratory analyses from a Phase 2 study of nipocalimab in moderate-to-severe SjD Argenx presented efgartigimod data showing long-term sustained patient benefit in myositis and SjD at EULAR-2026 JJP Biologics announces positive interim Phase 1b data for nebaprubart in Linear IgA Disease Spyre Therapeutics an